As demonstrated in Fig. 4b, metformin could significantly attenuate the IGF-1 induced activation of IGF-1R, AKT and ERK in a panel of NSCLC cell lines, which could at least partially explain the antitumor effects of metformin in Fig. 4a. Here, IGF1R is linked to non-small cell lung carcinoma.